Diabetic Retinopathy Drug Market to worth USD 705 Million by 2021

The global diabetic retinopathy drug market is anticipated to bolster at a robust growth rate to reach USD 705 Million by 2021. Geographically, the global diabetic retinopathy drug market is segmented into North America, Latin America, Western and Eastern Europe, Asia-Pacific, Middle East and North Africa (MENA) and Rest of World.

Diabetic retinopathy is a medical condition which damages retina (present at the back of eye) and leads to blindness if untreated or undiagnosed. The degree of treatment of diabetic retinopathy varies according to various stages of the disease and is mainly prioritized to curb the disease at its initial stage.

Growth Drivers and challenges

Rapidly expanding diabetic population coupled with increasing awareness of people regarding diabetic retinopathy is expected to drive the growth of global diabetic retinopathy drug market in coming 4-5 years.
In addition to that, rising medical procedures due to high penetration of medical insurance and rising government initiatives for prevention of diabetes related risks is also believed to garner the growth of global retinopathy drug market in future.

Get Full Table Of Content Diabetic Retinopathy Drug Market: http://www.researchnester.com/toc-request/1/rep-id-99

However, lack of trained ophthalmologist and stringent government regulations for approval of diabetic retinopathy drugs is anticipated to restrain the growth of global diabetic retinopathy drugs market over the forecast period i.e. 2015-2021.

Market Size and Forecast

Regionally, North America dominates the global diabetic retinopathy drug market. The region also accounted for 36.0% of total diabetic retinopathy market in 2015. Diabetic retinopathy drug market in the region is expected to escalate and get sparked by huge government spending on healthcare industry in coming 5-6 years.

Europe is the second largest diabetic retinopathy drug market behind North America. The market in the region is anticipated to propagate by increasing number of obese people, who are more prone to diabetes, in some of the major European countries including the U.K., Germany, Spain, France, Italy and Spain.

Asia-Pacific diabetic retinopathy drug market is believed to have the highest growth over the covered forecast period. Rapid expansion of diabetic population, increasing per capita income and major investments in health infrastructure are some of the key factors which are expected to propel the diabetic retinopathy drug market in countries such as India and China over next 4-5 years.
Japan diabetic retinopathy drug market is also anticipated to witness a burgeoned expansion fuelled by rapid growth of geriatric population in the country.

Key Players

Global diabetic retinopathy market is very competitive and includes some of the top players such as Roche, Moore Drug Company, Regeneron Pharmaceuticals Inc., Bayer Healthcare, ThromboGenics, Actavis PLC, Actavis PLC, Sirnaomics Incorporation, Parexel International Corp., etc.
Scope and Context
Overview of the Parent Market
Analyst View

Market Size and Growth

North America (U.S., Canada)
Latin America (Mexico, Brazil, Rest of Latin America)
Western and Eastern Europe (Germany, Italy, Spain, France, U.K, Benelux, Hungary, Rest Of Western Europe, Russia Poland, Rest of Eastern Europe)
Asia-Pacific (China, India, Singapore, Japan, Australia & New Zealand & Rest of Asia)
Rest of World

Read more about: http://www.researchnester.com/reports/global-diabetic-retinopathy-drug-market-analysis-opportunity-outlook-2021/99

Research Nester is a global market research and consulting firm helping organizations, private entities, governments undertaking, non-legislative associations and non-profit organizations. With our decades of experience in the market research, we help our clients to gain a competitive edge over other players. Thus, helping them making strategic yet dynamic decisions for the future investments.

Contact Us:
Ajay Daniel
Email: ajay.daniel@researchnester.com
1820 Avenue M, Suite# 1113,
Brooklyn, New York 11230
U.S. +1 646 586 9123

This release was published on openPR.